These findings are important because they represent real-world clinical practice data that support the efficacy and safety of linagliptin with a once-daily basal insulin injection in order to manage non-critically ill medicine department patients with T2D in the hospital. This evidence concerns the gene INS and type 2 diabetes mellitus.